Skip to content

Definiens Announces Agreement with Pfizer for eCognition Platform

Definiens AG, a leader in advanced image intelligence solutions, today
announced a collaboration with Pfizer Inc. (NYSE:PFE) for the global
implementation of Definiens’ eCognition™ Enterprise Image
Intelligence Solution.

Definiens will provide Pfizer with eCognition, a scalable,
hyper-spectral, hardware independent platform for image analysis that
can accommodate future innovations in imaging dyes and hardware. Under
the terms of the agreement, Pfizer will gain access to all the features
of the eCognition™ Enterprise Imaging Intelligence Solution along
with maintenance, training and consulting services from Definiens.
About Definiens
Definiens is a global leader in providing
advanced image intelligence solutions and services that enable its
clients to harness all relevant information from digital image to
support fast and accurate decision making crucial to its business
process. Definiens’ products are built on its platform technology
(eCognition) that represents a quantum leap in the realms of digital
image analysis. Our products are offered across chosen markets,
initially focusing on Earth Observation/Remote Sensing (EO/RS) and Life
Sciences. Definiens offers advanced and robust image analysis solutions
to accelerate the drug discovery, development, and diagnostics
processes in life sciences, and perform satellite and aerial image
classification more intelligently, accurately, and efficiently than
traditional methods. Definiens is a multi-national organization with
headquarters in Munich, Germany and offices in Boulder, Colorado and
Boston, Massachusetts. For further information regarding the company
and its products please visit
Definiens AG Andrea Mueller-Beilschmidt,
+49 (0)89 23 11 80-36
Mobile: +49 (0)171 76 66 518
Fax: +49 (0)89 23 11 80-90
(Credits Definiens)